Biogen Idec
|
Biogen Idec Inc. is engaged in the development, manufacturing, and commercialization of therapies. The Company’s products address diseases such as multiple sclerosis, lymphoma and rheumatoid arthritis. The Company has four products: AVONEX (interferon beta-1a), RITUXAN (rituximab), TYSABRI (natalizumab) and FUMADERM (dimethylfumarate and monoethylfumarate salts). AVONEX is used in the treatment of relapsing forms of multiple sclerosis (MS). RITUXAN is used in the treatment of relapsed or refractory low-grade or follicular, CD20-positive, and B-cell, non-Hodgkin’s lymphomas (B-cell NHLs). TYSABRI is approved for the treatment of relapsing forms of MS. FUMADERM acts as an immunomudulator. It a...
More from Zoominfo » |
Biogen Idec Job
- 8 Replies
Does anybody know anything about how to ge a job at Biogen Idec in San Diego? I've applied for a position I'm more than qualified for but I can't...
How to get a job at Biogen Idec.
- 2 Replies
Do you work at Biogen Idec? How did you find the job? How did you get that first interview?
Any advice for someone trying to get in?
Biogen Idec Salaries, Bonuses and Benefits.
What are the average starting salaries, bonuses, benefits and travel requirements like at Biogen Idec?
What do you like best about working at Biogen...
Biogen Idec Interview Questions.
It's always hard to know what to expect when going in for that interview -- and preparation can make all the difference. What is the interview...
What's the company culture at Biogen Idec?
Every business has it's own style. What is the office environment and culture like at Biogen Idec?
Are people dressed in business casual, jeans and...
More Biogen Idec discussions
|
|
Biogen Idec drops baminercept for RA
Fortunately for Biogen, analysts hadn't factored the drug's sales into the company's future performance. "We view this as largely a nonevent for Biogen shares as baminercept was not in our model and (Wall) Street expectations for the ...
From
Untitled
- by Maureen Martino - 1 day ago
Biogen Idec, Inc.
(RTTNews) - Thursday, Biogen Idec said its rheumatoid arthritis drug candidate baminercept failed to meet both primary and secondary endpoints in its Phase II trial and added that it would discontinue the development of the compound in ...
From
biospace.com Featured News
- 1 day ago
Biogen Idec Inc
BUY rating on Biogen Idec Inc (BIIB) Start Price: $42.78 Start Date: 10/11/2008.
From
socialpicks.com: Recent Picks
- by Mike Havrilla - 6 hours ago
More blog posts from Google Blog Search
|
|
